A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics, and Antitumor Activity of a Chimeric Degradation Activating Compound (CDAC) Degrading Epidermal Growth Factor Receptor (EGFR), BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)